Unlock this StockReport nowClick to Unlock

Danaher Share Price

DHR $139.63 0.2  0.2%
14/06/19
StockRank

Momentum
Relative Strength (%)
1m
3m
1yr
Volume Change (%)
10d v 3m
Price vs... (%)
52w High
50d MA
200d MA
vs.
market
vs.
industry
Growth & Value
Margin of Safety (beta)
Screens Passed
Balance Sheet · Income Statement · Cashflow Financial Summary
Year End 31st Dec 2013 2014 2015 2016 2017 2018 TTM 2019E 2020E CAGR / Avg
Revenue $m
Operating Profit $m
Net Profit $m
EPS Reported $
EPS Normalised $
EPS Growth %
PE Ratio x
PEG x
Profitability
Operating Margin %
ROA %
ROCE %
ROE %
Cashflow
Op. Cashflow ps $
Capex ps $
Free Cashflow ps $
Last ex-div: 27th Jun, paid: 26th Jul more... Dividends
Dividend ps $
Dividend Growth %
Dividend Yield %
Dividend Cover x
Balance Sheet
Cash etc $m
Working Capital $m
Net Fixed Assets $m
Net Debt $m
Book Value $m
Average Shares m
Book Value ps $ +4.6%

FINANCIAL BRIEF: For the three months ended 29 March 2019, Danaher Corporation revenues increased 4% to $4.88B. Net income applicable to common stockholders decreased 42% to $327.3M. Revenues reflect Life sciences segment increase of 10% to $1.63B, Environmental & Applied Solutions segment increase of 3% to $1.06B, DIAGNOSTICS segment increase of 1% to $1.54B. Net income was offset by Other segment loss increase from $54.4M to $111.1M. more »

Health Trend
Bankruptcy Risk
  Earnings Manipulation Risk
Magic Formula Score
B+
B+
Other Ratios
Leverage (ttm) Total -Intang +Pension
Gross Gearing %
Net Gearing %
Cash / Assets %
vs.
market
vs.
industry
Recent History
Latest interim period (ended 29th Mar '19) vs. prior year
Sales Growth %
EPS Growth %
3yr Compound Annual Growth Rate
Sales Growth %
EPS Growth %
DPS Growth %

Broker Forecasts
31st Dec 2019
31st Dec 2020

Price Target: $144.6
(+3.61% above Price)
Net Profit EPS DPS Net Profit EPS DPS
Est. Long Term Growth Rate: +8.6% ($) ($) ($) ($) ($) ($)
Consensus Estimate
1m Change
3m Change
13 brokers Broker Consensus Trend
Broker Recommendations for Danaher
Recommendation:Strong SellSellHoldBuyStrong Buy
No. of Analysts: 0 0 2 8 7

Named Brokers and Analysts
Bank of America Merrill Lynch Andrew Obin , Deutsche Bank Dan Leonard , Janney Montgomery Scott LLC Paul Knight , Cowen and Company Douglas Schenkel , Stifel Nicolaus and Company, Incorporated , Needham & Company Inc. Stephen Unger , Jefferies Brandon Couillard , Credit Suisse - North America Julian Mitchell , RBC Capital Markets Deane Dray , Morgan Stanley , Citi , SVB Leerink , Wells Fargo Securities, LLC , Goldman Sachs Research Isaac Ro , Argus Research Corporation John Eade , Robert W. Baird & Co. Richard Eastman , William Blair & Company Brian Drab , UBS Equities , JPMorgan Tycho Peterson , CRT Capital (Historical) , Wolfe Research Steve Beuchaw , Barclays Julian Mitchell , Morningstar, Inc. Michael Waterhouse , EVERCORE ISI Ross Muken , BTIG , Melius Research Scott Davis ,

Profile Summary

Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification. As of December 31, 2016, Danaher's research and development, manufacturing, sales, distribution, service and administrative facilities were located in over 60 countries.

Directors: Steven Rales (CHM) 68, Matthew McGrew (CFO) 47, Rainer Blair (EVP) 54, Daniel Comas (EVP) 55, William Daniel (EVP) 54, Joakim Weidemanis (EVP) 49, Robert Lutz (SVP) 61, Brian Ellis (SVP) 52, Angela Lalor (SVP) 53, William King (SVP) 51, Donald Ehrlich (LED) 81, Mitchell Rales (DRC) 62, Linda Hefner Filler (IND) 58, Teri List-Stoll (IND) 56, Walter Lohr, (IND) 75,

No. of Employees: 71,000 No. of Shareholders: 2,500


Last Annual December 31st, 2018
Last Interim March 29th, 2019
Incorporated October 3, 1986
Public Since July 10, 2015
Shares in Issue 715,933,649
Free Float 635.7m (88.8%)
Sector Healthcare
Industry Healthcare Equipment & Supplies
Index S&P Composite 1500 , S&P 500 , S&P 500 Health Care (sector),
Exchange New York Stock Exchange
Eligible for an ISA? a SIPP?

DHR Share Price Performance DHR Share Price Quote
$139.63
0.2  0.2%
Traded 9:02pm · Minimum 15 min delayed · NMS:

Latest DHR News Announcements (delayed)

Upcoming DHR Events
Thursday 27th June, 2019
Dividend For DHER34.SA
Thursday 27th June, 2019
Dividend For DHR.N
Wednesday 17th July, 2019 (estimate)
Q2 2019 Danaher Corp Earnings Release
Wednesday 16th October, 2019 (estimate)
Q3 2019 Danaher Corp Earnings Release

Recent ↓
Thursday 30th May, 2019
Danaher Corp at Sanford C Bernstein Strategic Decisions Conference
Wednesday 15th May, 2019
Danaher Corp at Bank of America Merrill Lynch Health Care Conference
Tuesday 7th May, 2019
Danaher Corp Annual Shareholders Meeting
Thursday 18th April, 2019
Q1 2019 Danaher Corp Earnings Call
Thursday 18th April, 2019
Q1 2019 Danaher Corp Earnings Release
Thursday 28th March, 2019
Dividend For DHR.N
Wednesday 27th March, 2019
Dividend For DHER34.SA
Wednesday 20th February, 2019
Danaher Corp at Barclays Industrial Select Conference
Tuesday 29th January, 2019
Q4 2018 Danaher Corp Earnings Call
Tuesday 29th January, 2019
Q4 2018 Danaher Corp Earnings Release
Tuesday 8th January, 2019
Danaher Corp at JPMorgan Global Healthcare Conference
Thursday 27th December, 2018
Dividend For DHR.N
Thursday 13th December, 2018
Danaher Corp Investor and Analyst Meeting
Tuesday 6th November, 2018
Danaher Corp at Robert W Baird Global Industrial Conference
Thursday 18th October, 2018
Q3 2018 Danaher Corp Earnings Call
Thursday 18th October, 2018
Q3 2018 Danaher Corp Earnings Release
Thursday 27th September, 2018
Dividend For DHR.N
Tuesday 18th September, 2018
Danaher Corp Investor & Analyst Event
Friday 14th September, 2018
Danaher Corp at Morgan Stanley Healthcare Conference
Thursday 19th July, 2018
Q2 2018 Danaher Corp Earnings Call


Use of our data service is subject to express Terms of Service. Please see our full site disclaimer for more details. In particular, it is very important to do your own research (DYOR) and seek professional advice before making any investment based on your own personal circumstances. Please note that the information, data and analysis contained within this stock report: (a) include the proprietary information of Stockopedia's third party licensors and Stockopedia; (b) should not be copied or redistributed except as specifically authorised; and (c) are not warranted to be complete, accurate or timely. You should independently research and verify any information that you find in this report. Stockopedia will not be liable in respect of any loss, trading or otherwise, that you may suffer arising out of such information or any reliance you may place upon it. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. © Stockopedia 2019.


Should you buy DHR

Access DHR Analytics Now!

FREE TRIAL or TAKE THE TOUR
Let’s get you setup so you get the most out of our service
Done, Let's add some stocks
Brilliant - You've created a folio! Now let's add some stocks to it.

  • Apple (AAPL)

  • Shell (RDSA)

  • Twitter (TWTR)

  • Volkswagon AG (VOK)

  • McDonalds (MCD)

  • Vodafone (VOD)

  • Barratt Homes (BDEV)

  • Microsoft (MSFT)

  • Tesco (TSCO)
Save and show me my analysis